Finerenone Side Effects

Medically reviewed by Drugs.com. Last updated on Jul 7, 2024.

Applies to finerenone: oral tablet.

Precautions

It is very important that your doctor check your progress at regular visits, especially during the first few weeks that you take this medicine. Blood tests may be needed to check for unwanted effects.

You should not use this medicine if you are also using efavirenz, itraconazole, or rifampicin.

This medicine may cause hyperkalemia (high potassium in the blood). Check with your doctor right away if you have confusion, irregular heartbeat, nausea or vomiting, nervousness, numbness or tingling in the hands, feet, or lips, stomach pain, trouble breathing, or weakness or heaviness of the legs.

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements (eg, potassium supplements).

Serious side effects of finerenone

Along with its needed effects, finerenone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking finerenone:

For healthcare professionals

Applies to finerenone: oral tablet.

General adverse events

The most frequently reported adverse reaction was hyperkalemia.^[Ref]

Cardiovascular

• Common (1% to 10%): Hypotension (includes blood pressure decreased, diastolic blood pressure decreased, diastolic hypotension, hypotension)
• Frequency not reported: Systolic blood pressured decreased, diastolic blood pressure decreased^[Ref]

In patients treated with this drug, the mean systolic and diastolic blood pressure decreased by 2 to 4 mmHg and 1 to 2 mmHg, respectively, at month 1 and remained stable thereafter. Most hypotension events were mild or moderate and resolved; events associated with hypotension (e.g., dizziness, syncope, fall) were not more frequent in patients treated with this drug compared to placebo.^[Ref]

Dermatologic

• Common (1% to 10%): Pruritus^[Ref]

Hematologic

• Common (1% to 10%): Anemia
• Uncommon (0.1% to 1%): Hemoglobin decreased
• Frequency not reported: Hematocrit decreased^[Ref]

Metabolic

• Very common (10% or more): Serum potassium increased (up to 21.7%), hyperkalemia (includes blood potassium increased, hyperkalemia; up to 18.3%)
• Common (1% to 10%): Hyponatremia (includes blood sodium decreased, hyponatremia)^[Ref]

In a study, hyperkalemia events were reported in 18.3% of patients treated with this drug; most hyperkalemia events were mild to moderate in patients treated with this drug. Serious hyperkalemia events were report more often for this drug than placebo; serum potassium levels greater than 5.5 mmol/L and greater than 6 mmol/L were reported in 21.7% and 4.5% of patients treated with this drug and in 9.8% and 1.4% of those treated with placebo, respectively.

An increase from baseline in mean serum potassium in the first month of therapy was about 0.2 mmol/L in patients treated with this drug.^[Ref]

Nervous system

• Frequency not reported: Dizziness, syncope^[Ref]

Other

• Frequency not reported: Fall^[Ref]

Renal

• Common (1% to 10%): Estimated glomerular filtration rate (eGFR) decreased/GFR decreased^[Ref]

This drug caused an initial small decrease in eGFR (mean 2 mL/min/1.73 m2); it occurred within the first 4 weeks of therapy and then stabilized. In a study including patients with chronic kidney disease associated with type 2 diabetes, this decrease was reversible after therapy was stopped.^[Ref]

See also:

Further information

Finerenone side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer